Cite
Merat S, Sharifi AH, Poustchi H, et al. Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial. Clin Infect Dis. 2021;73(1):172doi: 10.1093/cid/ciaa1768.
Merat, S., Sharifi, A. H., Poustchi, H., Hajiani, E., Gharavi, A., Karimi, J., Mansour-Ghanaei, F., Fattahi, M. R., Ahmadi, L., Somi, M. H., Kalantari, H., Ghadir, M. R., Sheikhesmaeili, F., Baniasadi, N., Sohrabi, M., Moosavy, S., Ziaee, M., Zahedi, M. J., Mokhtare, M., Sali, S., Sayad, B., Afshar, B., Bakhshipour, A., Parsi, A., Sharifian, A., Amiriani, T., Malekzadeh, Z., Merat, D., Ganji, A., Rahmani-Samani, F., Jamali, R., Sofian, M., Ghezlou, M., Sohrabpour, A. A., Goshayeshi, L., Valizadeh-Toosi, S. M., Eslami, L., Maleki, I., Hormati, A., Shayesteh, A. A., Shayesteh, E., Norouzi, A., Abna, Z., Janbakhsh, A., Fakheri, H., Minakari, M., Sardarian, H., Ghajary, A. F. A., Fattahi-Abdizadeh, M., Latifnia, M., Roozbeh, F., Agah, S., Fakhrieh-Asl, S., Nateghi-Baygi, A., Fattahi, B., Nateghi-Baygi, H., Hill, A., & Malekzadeh, R. (2021). Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73(1), 172. https://doi.org/10.1093/cid/ciaa1768
Merat, Shahin, et al. "Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 73,1 (2021): 172. doi: https://doi.org/10.1093/cid/ciaa1768
Merat S, Sharifi AH, Poustchi H, Hajiani E, Gharavi A, Karimi J, Mansour-Ghanaei F, Fattahi MR, Ahmadi L, Somi MH, Kalantari H, Ghadir MR, Sheikhesmaeili F, Baniasadi N, Sohrabi M, Moosavy S, Ziaee M, Zahedi MJ, Mokhtare M, Sali S, Sayad B, Afshar B, Bakhshipour A, Parsi A, Sharifian A, Amiriani T, Malekzadeh Z, Merat D, Ganji A, Rahmani-Samani F, Jamali R, Sofian M, Ghezlou M, Sohrabpour AA, Goshayeshi L, Valizadeh-Toosi SM, Eslami L, Maleki I, Hormati A, Shayesteh AA, Shayesteh E, Norouzi A, Abna Z, Janbakhsh A, Fakheri H, Minakari M, Sardarian H, Ghajary AFA, Fattahi-Abdizadeh M, Latifnia M, Roozbeh F, Agah S, Fakhrieh-Asl S, Nateghi-Baygi A, Fattahi B, Nateghi-Baygi H, Hill A, Malekzadeh R. Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial. Clin Infect Dis. 2021 Jul 01;73(1):172. doi: 10.1093/cid/ciaa1768. PMID: 33857308.
Copy
Download .nbib